SATURDAY, NOVEMBER 23
SURVIVORS TEACHING STUDENTS TRAINING
Survivors Teaching Students (STS) is a national outreach program sponsored by the Ovarian Cancer National Alliance (OCNA) to raise awareness of ovarian cancer symptoms and risks among medical students.
As a partner member of OCNA, Rhonda’s Club meets year-round with students at Georgetown, George Washington and Johns Hopkins medical schools. At each class, three ovarian cancer survivors, assisted by a moderator, share their personal cancer journeys and answer questions from the students. The response to this program has been overwhelmingly positive from both medical students and survivors.
Rhonda’s Club will be training new speakers for Survivors Teaching Students on Saturday, November 23 from 11:00 to 3:00 at the Potomac Community Center in Potomac, Maryland. We will help you tell your story in your own words. No previous public speaking experience is necessary. Once you are trained, your participation in STS is determined by your availability. Many survivors have found STS to be an effective way to get their message out to future doctors in the hope that the disease can be detected earlier and more lives saved.
To register, please contact Fran Stolusky at 301-299-9369 or leave a message at Rhonda’s Club: 703-346-3893.
On Thursday, November 21st, at 6 p.m. EST, we invite you to join Ronny Drapkin, M.D., Ph.D., Assistant Professor at Harvard Medical School, Associate Pathologist at Brigham and Women's Hospital and Principle Investigator at the Dana-Farber Cancer Institute, for the free educational webinar, "Exploring the Origins of Ovarian Cancer."
Dr. Drapkin will discuss why this is an important area of scientific research, and will talk specifically about his research which suggests that many serous ovarian cancers may originate in the fallopain tube. He will also discuss the important implications of this research for ovarian cancer prevention and detection strategies.
You can listen in and ask questions live by registering here.
Please note, the webinar is not accessible via iPad or mobile device at this time.
This will be OCRF's last webinar of the year. The archived webinar will be available for viewing following the original presentation. All registered participants will receive an alert when the archived webinar is available.
All past webinars are currently viewable here
. This series is made possible with the support of Genentech.
A Radioshow for Cancer Patients
Listen to "Frankly Speaking About Cancer" every Tuesday at 4pm eastern time (1pm pacific time). The host is Kim Thiboldeaux, President and CEO of the Cancer Support Community, stives to empower her listeners to live well with cancer. Click here to visit the website. You can also find past episodes available for listening!
OGCC/RHONDA'S CLUB ACTIVITIES
We thank our generous sponsors of the 2013 Survivors Tea!
Mid Atlantic Gynecologic Oncology and Pelvic Surgery Associates
Clare and Kevin Donelan
Fran and Warren Stolusky
JoAnn and Howard Symons
Seggerman Homes, LLC
Mighty Leaf Tea
The Republic of Tea
Is Your Body Talking? Take Time to Listen
Ovarian and Endometrial Cancer Survivor Stories
DC Department of Health, DC Cancer Consortium, and OGCC/Rhonda's Club partnered to conduct an interpersonal study of women who have survived ovarian and endometrial cancers.
SURVIVOR EDUCATION PROGRAM
The Future of Ovarian & Gynecologic Cancer, presented by Dr. Michael V. Seiden, MD, PhD, President and CEO of Fox Chase Cancer Center, Philadelphia, PA, to Rhonda's Club on September 12, 2011.
Click on the image above to watch the video.
Click here to download slides accompanying Dr. Michael V. Seiden's presentation.
view our calendar of events >
New Study Confirms Importance of Treatment by Gynecologic Oncologists
New research presented at the annual meeting of the Society of Gynecologic Oncologists in early March confirmed the critical importance of seeking treatment for ovarian cancer from a gynecologic oncologist. The study, led by Dr. Robert E. Bristow, found most women with ovarian cancer receive less than optimal care because they see doctors who do not specialize in treating ovarian cancer. The five-year survival rate and disease-free intervals of patients treated by gynecologic oncologists far surpass those of patients whose surgeons were not gynecologic oncologists. To read more about this new research, CLICK HERE.
New Hope for Early Detection of Ovarian and Endometrial Cancers
Cara Tenenbaum, Vice President for Policy and External Affairs at OCNA and a Rhonda's Club board member, reports that a small study of 46 women showed that examining cells on the cervix with the Pap test can help identify ovarian and uterine cancers. In this study, DNA analysis detected 41% of ovarian cancer cases. For more information, read the article on msnbc.msn.com or nytimes.com.
Cervical Cancer Screening
The U.S. Preventive Services Task Force announced on March 14, 2012 its final recommendation on screening for cervical cancer. For more information, CLICK HERE.
Ovarian Cancer Advocates Troubled by FDA Decision on Avastin and Breast Cancer
Posted by the Ovarian Cancer National Alliance (OCNA)
On November 18, 2011 the Food and Drug Administration (FDA) announced that it would remove metastatic breast cancer from the label for Avastin (bevacizumab). This decision follows recommendations made in June by the FDA Oncologic Drugs Advisory Committee. Responding to today’s decision, OCNA CEO Karen Orloff Kaplan, MSW, MPH, ScD, expressed concern that the removal of metastatic breast cancer from the Avastin label could negatively affect women with ovarian cancer, for whom the drug is used off-label. read more >>
Ovarian Cancer Patients with BRCA Mutations May Fare Better than Non-Carriers
A large, multicenter study shows that women with ovarian cancer who have mutations in the BRCA1 or BRCA2 genes have better survival rates than women who do not have such mutations. The study is also the first to provide strong evidence that ovarian cancer prognosis is better for women with BRCA2 mutations than women with BRCA1 mutations. The results were published online today in JAMA. Inherited mutations in BRCA1 and BRCA2 are the strongest known genetic risk factors for breast cancer and epithelial ovarian cancer, the most common form of ovarian cancer. To read more click here.
more resources >